News

32nd World Congress of the World Society of Cardiovascular and Thoracic Surgeons


The 32nd World Congress of the World Society of Cardiovascular and Thoracic Surgeons (WSCTS), is going to be held in Barcelona, Spain, between the 5th and the 7th of September, 2024. Within the session “Cardiovascular Tissue Banking” Dr. Sarikouch is going to present “Long-term results of modern homografts”. Decellularized pulmonary and aortic homografts have been studied in prospective European-wide multi-center settings and 5-year data for decellularized pulmonary as well as for decellularized aortic homografts have been published within the European Journal for Cardiothoracic surgery together with long-term data from the ESPOIR and ARISE Registries.

 

 https://academic.oup.com/ejcts/article/62/5/ezac219/6568944

 

https://academic.oup.com/ejcts/article/65/4/ezae121/7635581





EACTS 2nd Innovation Summit, 18-20. April, Paris


The 2nd EACTS Innovation Summit was held at the Chateau Les Pres d`Ecoublay near Paris this April. Sessions were dedicated to the “Future of Robotic Surgery”, “Extracorporal Circulation”, “Artificial Intelligence for Cardiothoracic Surgery” and the “Heart valve of the future”. Within this latter session, Dr. Sarikouch presented the results of two European-wide studies on decellularized homografts for pulmonary and aortic valve replacement as well as an outlook for decellularized allogenic heart valves derived from genetically modified animals.

 

https://www.eacts.org/our-community/news-hub/eacts-hosts-paris-innovation-summit/


Serial assessment of early antibody binding to decellularized valved allografts.


Decellularized homografts (DHV) are currently the only clinically applied tissue-engineered heart valves and have shown superior performance in comparison with conventional cryopreserved allografts in a recent meta-analysis for pulmonary valve replacement.(Waqanivavalagi S et al. Clinical performance of decellularized heart valves versus standard tissue conduits: a systematic review and meta-analysis. J Cardiothorac Surg. 2020)


Despite almost complete decellularization, documented by standard microscopy and very low residual DNA content, DHV seem to elicit an immune response that appears to be stronger in younger recipients, indicated by progressing valve dysfunction. This has been observed especially in decellularized aortic homografts (DAH) recipients and may be explained by the fact that aortic homografts are considerably thicker, thereby potentially carrying more antigenic material. Classic T-cell-mediated immune response, considered to be the leading mechanism for the usually relatively slow mode of degeneration in cryopreserved heart valves, may not be the key mechanism in DHV degeneration.


The purpose of the current analysis was to measure antibody binding to DHV in patients with repaired congenital heart disease. Our aim was to (1) compare the amount of baseline preformed antibody binding in patients who had received different patch material and different heart valve substitutes to levels of antibody binding in healthy controls, and (2) to analyze the early impact of DHV implantation in these patients using the Dot-Blot test and echocardiography.


https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.895943/full


Share by: